Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Conditions: Adult T-Cell Lymphoma/Leukemia; Sezary Syndrome; Mycosis Fungoides Interventions: Drug: rhIL-15; Biological: Mogamulizumab Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2019 Category: Research Source Type: clinical trials
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Conditions: Adult T-Cell Lymphoma/Leukemia; Sezary Syndrome; Mycosis Fungoides Interventions: Drug: rhIL-15; Biological: Mogamulizumab Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2019 Category: Research Source Type: clinical trials
Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Conditions: Mycosis Fungoides; Sezary Syndrome; Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage III Myco sis Fungoides and Sezary Syndrome AJCC v8; Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA2 M ycosis Fungoides ...
Source: ClinicalTrials.gov - October 4, 2018 Category: Research Source Type: clinical trials
